IDO1 and asthma: Furthermore, in mice treated with IDO-KO ASCs, treated mice showed reductions in AHR, inflammatory cells in BALF, lung inflammation, asthma-specific cytokines in BALF and LLN, and serum levels of Th2 immunoglobulins.